anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Certain long non-coding RNAs (lncRNAs) have potential peptide-coding abilities. Here, the role and molecular basis of the RNF217-AS1-encoded peptide in stomach cancer (SC) tumorigenesis were explored. Here, lncRNAs associated with SC pathogenesis and macrophage infiltration and lncRNAs with peptide-coding potential were searched by bioinformatics analysis. The gene mRNA and protein levels were examined by RT-qPCR and western blot assays, respectively. Cell viability, migratory, and invasive abilities were measured by CCK-8, Transwell migration, and Transwell invasion assays, respectively. The potential biological processes related to lncRNA RNF217-AS1 were identified by single-gene GSEA analysis. The effect of RNF217-AS1-encoded peptide on SC tumorigenesis was examined by mouse xenograft experiments. The results showed that lncRNA NR2F1-AS1 and RNF217-AS1 were differentially expressed and associated with macrophage infiltration in SC, and they had the ability to translate into short peptides. The RNF217-AS1 ORF-encoded peptide could reduce SC cell viability, inhibit cell migration and invasion, as well as hinder the development of SC xenograft tumors. The RNF217-AS1 ORF-encoded peptide in human SC AGS cells suppressed THP-1 cell migration, triggered the differential expression of CXCL1/CXCL2/CXCL8/CXCL12, and inactivated the TLR4/NF-κB/STAT1 signaling pathways. As a conclusion, the RNF217-AS1 ORF-encoded peptide hindered SC progression in vitro and in vivo and suppressed macrophage recruitment and pro-inflammatory responses in SC.
Pregnancy Category D for women with mechanical heart valves [see Warnings and Precautions (5.5)] and Pregnancy Category X for other pregnant populations [see Contraindications (4)]. 

Warfarin sodium tablets are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism, and for whom the benefits of warfarin sodium may outweigh the risks. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy), fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. The reproductive and developmental effects of warfarin sodium have not been evaluated in animals. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. 

In humans, warfarin crosses the placenta, and concentrations in fetal plasma approach the maternal values. Exposure to warfarin during the first trimester of pregnancy caused a pattern of congenital malformations in about 5% of exposed offspring. Warfarin embryopathy is characterized by nasal hypoplasia with or without stippled epiphyses (chondrodysplasia punctata) and growth retardation (including low birth weight). Central nervous system and eye abnormalities have also been reported, including dorsal midline dysplasia characterized by agenesis of the corpus callosum, Dandy-Walker malformation, midline cerebellar atrophy, and ventral midline dysplasia characterized by optic atrophy. Mental retardation, blindness, schizencephaly, microcephaly, hydrocephalus, and other adverse pregnancy outcomes have been reported following warfarin exposure during the second and third trimesters of pregnancy [see Contraindications (4) and Warnings and Precautions (5.6)].
1. A method for the production of spherical telithromycin clusters, characterized in that a telithromycin crystal suspension is prepared, said crystals are coated with a telithromycin insoluble phase which gradually crystallizes. 2. The method according to claim 1, characterized in that using telithromycin suspension in acetone. 3. The method according to claim 1 or 2, characterized in that crystallization is carried out in a mixture of acetone and diisopropyl ether. 4. The method according to any one of claims 1-3, characterized in that crystallization is carried out at a temperature from -5 degree to -15 degree C. 5. Use of spherical telithromycin clusters produced according to claims 1-4 for the preparation of micro-capsules of pharmaceutical forms coated with a polymer layer to obtain a desirable galena form.
The present invention relates to the production art of the prostaglandin E2 injection. The purity degree is low in prostaglandin E2 production of the current technology. The stability is poor and the clinical application method is complicated. The prostaglandin E2 crystallization is prepared by high purity synthesis and purification technology of arachidonic acid. With the improvement of  the stability and water solubility of the product, controllability of the product quality is improved. The clinical application method is greatly simplified. Product of the present invention is the prostaglandin E2 injection of high purity, high stability, high homogeneity, convenient clinical application and high therapy effect. In clinical application, the prostaglandin E2 injection is mainly applied in full-term induced labor and induced spawning, which is a new chemical preparation unlikely to cause fetus asphyxia and uterine rupture.
Certain examples provide system and methods for population health management. An example population health management system includes an information exchange platform, a knowledge platform, application(s), and a user portal. The example information exchange platform is to share of information for patients and providers in a selected population. The example information exchange platform is to collect and transform the information into an accessible, sharable format. The example knowledge platform is to derive insight from the collected and transformed information. The example knowledge platform is to facilitate application of one or more analytics and rules-based workflows to the collected and transformed information to derive insight. The example application(s) are to coordinate communication and care collaboration across the selection population based on the insight and information. The example user portal is to provide a unified interface to enable access to the application(s), knowledge platform, and information for the selected population.
Standard procedures of the clinic were applied to control group. According to the standard practice of the clinic, it was performed tanflex (3x1) and/or sodium bicarbonate (1x1) to the patients in the prevention of oral mucositis with the request of the physician. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
The present invention relates to an Ankang capsule for abstaining from drugs. The present invention is suitable for treating drug abstaining symptoms generated in the process of stopping drug addiction. The present invention is characterized in that a given amount of extractum hyoscyami powder, nefopami hydrochloride, chlortrimeton and medical starch are thoroughly and uniformly mixed; after subpackage, finished products are obtained. The present invention radically solves the key problem that when drug addiction is stopped, new addiction is formed. The present invention has the functions of relieving pain, resisting allergy, relieving spasm of smooth muscles, inhibiting glandular secretion, etc. The present invention is especially suitable for treating drug abstaining symptoms, such as pain, allergy, anxiety, insomnia, sudation, nasal discharge, diarrhea, etc., generated after addicts' drug addiction is stopped.
FIELD: medicine, dermatovenerology. SUBSTANCE: method involves topical treatment using timrostim solution taken in dilution = 1:7 - 1:10, time of treatment is 10-15 min, course is 15-20 procedures. Method allows to decrease number of disease relapses and adverse effects of antibiotic therapy. Invention can be used for treatment of patients with gonorrhea. EFFECT: improved method of treatment. 2 cl, 2 tbl
PURPOSE:To facilitate handling at the time of the pressure contact with a diagnostic model to impart allowance to an operating time, to achieve the accurate fitness to the model by pressure contact, to perform short-time curing at the time of curing and to obtain an accurate impression without generating deformation when a final impression is collected even if a cured body is thin, by using photopolymerizable FRP. CONSTITUTION:In general, the ratio of an unsaturated polyester resin or radical polymerizable monomer and/or a radical polymerizable oligomer allowed to impregnate a fiber is set so that the ratio of (fiber)/(unsaturated polyester resin or radical polymerizable monomer and/or radical polymerizable oligomer) is about 0.05-1.0 on a wt. basis and consistency easy to operate at the time of the pressure contact of photopolymerizable FRP on a diagnostic model 1 is obtained. In the case of the sheet like photopolymerizable FRP, it is convenient to preliminarily bore holes having a diameter of 1- several mm in the FRP in order to hold an impression material 4. The temp. at the time of photo-setting is usually 0-60 deg.C, pref., 5-50 deg.C and a light irradiation time is usually 1sec-7 min.
Methylphenidate hydrochloride extended-release tablets use a precisely designed diffusion process to deliver methylphenidate hydrochloride at a controlled rate. The system comprises a polymeric core surrounded by a diffusion controlling membrane with an immediate release drug overcoat. In an aqueous environment, such as the gastrointestinal tract, the drug overcoat dissolves within one hour, providing an initial dose of methylphenidate. Water enters the tablet core through the diffusion controlling membrane, and methylphenidate is released in a controlled fashion resulting in Cmax at 6 to 7 hours. The non-absorbed components of the tablet pass through the gastrointestinal tract and are eliminated in the stool. It is possible that methylphenidate hydrochloride extended-release tablets may be visible on abdominal x-rays under certain circumstances, especially when digital enhancing techniques are utilized. 

Meets USP Dissolution Test 4.
The invention discloses a Chinese patent medicine ear-drop preparation containing Shuanghuangliang and andrographolide. Furacilin ear drops are external use local antibacterial agents which are frequently used clinically in the ear-nose-throat department of a hospital in China. Furacilin ear drops which are prepared through a traditional method have the following defects that stability is poor, the color can be darkened easily in the storage and clinical use process, and pale brown crystals can be precipitated from furacilin easily under the low-temperature condition in winter; heating and long-term stirring are needed during preparation; the content of the furacilin can be lowered at varying degrees along with the number of the crystals, so that the clinical effect is lowered, and the furacilin cannot be used. The furacilin ear drops prepared through the method are greatly optimized in technology. The phenomena of crystallization, turbidness and the like cannot happen to the obtained product through observation of reserved samples for 24 months, and high stability is achieved. The content of the furacilin is determined through the ultraviolet-visible spectrophotometry, the content is not changed obviously during the period of storage, and the content loss percentage is smaller than 1%.
STUDY DESIGN: Systematic review of Randomised controlled trials.
OBJECTIVES: With the increasing incidence of back pain among children and its untold implications to their future, back education tailored in an effective way would be indicated. However literature appears unsettled. This study aims to review available literature to determine the effect of school-based back education in preventing and managing low back pain in school children.
METHODS: Randomized controlled trials carried out on elementary and secondary school children of ages 6 to 18 years and published in English language were included. Back education taught in hospitals or other settings were excluded. Primary outcome was back pain prevalence and secondary outcomes were constituted from the study characteristics of selected studies which includes: back behavior, knowledge, postural habits, physical activity, fear-avoidance beliefs, back pack carriage, pain intensity, skills and self efficacy. Databases searched were PEDro, HINARI, PubMed, Cochrane, and Google Scholar. Available stiudies from 2000 to March 2022 were retrieved. Quality of studies were assessed using the PEDro scale. Obtained studies were descriptively analyzed.
RESULTS: A total 8420 studies were retrieved and 8 studies (with 1239 participants) were included in this review. Four studies each assessed back knowledge and back behavior, and two assessed back pain prevalence. There were improvements in back knowledge and back behaviour, but effectiveness of back care education on back pain prevalence was not conclusive. Forms of education used involved the indirect method of conditioning the environment and the direct method which made use of theory, practical lessons and educational books and materials.
CONCLUSION: Back care education programmes in schools are effective in improving back care knowledge, behavior and reduction in low back pain frequency. Reduction in back pain prevalence is not conclusive. Back care education could be incorporated as part of schools' education programmes. Limitations include exclusion of non English language studies and inconsistent outcome measures.
FUNDING SOURCE: None.
REGISTRATION: This review protocol was registered under the International platform of Registered systematic review and meta-analysis protocol (INPLASY) with the registration number; INPLASY202310044 and DOI number; https://doi.org/10.37766/inplasy2023.1.0044.
OBJECTIVES: Despite the well-established association between prediabetes and hyperuricaemia, knowledge about serum urate (SU) trends during the prediabetic phase is limited. Therefore, we aimed to assess the longitudinal changes of SU in individuals with prediabetes.
METHODS: Individuals with prediabetes, defined by initial haemoglobin A1c (HbA1c) levels between 5.7% and 6.4%, were identified using electronic health records from an academic health system (2007-2022). We required at least one SU test before and after the prediabetes diagnosis. The primary outcome was the longitudinal SU trends during the follow-up period, estimated with a multivariable mixed-effects model. Patients were censored at diabetes onset. Marginal effects of covariates on SU changes were estimated. Subsequent analyses examined SU variations in subgroups stratified by age, sex, BMI, HbA1c, estimated glomerular filtration rate and metformin use.
RESULTS: Out of 25 526 individuals with prediabetes, 1521 met the SU cohort requirements, contributing to 6832 SU observations. At baseline, median age was 63 years and 40% were female. Median values were SU 6.3 mg/dl, HbA1c 5.9% and BMI 30 kg/m2. Median follow-up was 7.4 years. Older age, male sex, greater BMI and higher HbA1c were significant predictors of increased longitudinal SU levels. Individuals with a BMI ≥30 kg/m2 exhibited higher SU levels compared with those with lower BMI values.
CONCLUSION: Among individuals with prediabetes, several baseline variables were significant predictors of increased SU levels over time. These longitudinal trends in SU, support the potential for early intervention during the prediabetic phase, possibly reducing the risk of gout.
FIELD: medicine. SUBSTANCE: recipe includes sodium bromide, boric acid, sugar and distilled water. The recipe is also compatible when sugar is substituted with glucose. The recipe is for external use as fomentation. Cotton wool tampons, cotton wool and gauze bandages are used as preparation carriers. Treatment course duration is 2-30 days long being adjustable as a result of visual inspection with disease symptoms vanishing. EFFECT: enhanced effectiveness of treatment. 2 cl
PURPOSE:To obtain a polyion complex containing hyarulonic acid and a cationic polyacrylic acid derivative and useful as a carrier for preparation. CONSTITUTION:Hyarulonic acid is blended with a cationic polyacrylic acid derivative so as to form a polyion complex. If this polyion complex is used as a carrier for preparation, an internal-type sustained-release preparation exhibiting excellent sustained-release properties and capable of controlling the release-starting time and the release period can be obtained by blending a bioactive substance (e.g. noscarpine drochloride) therewith. In addition, the raw materials can be obtained without fail and ready preparation is possible. Sufficient sustained-release properties are exhibited and the active component can be released over several or more days without collapse of the shape of the preparation.
Patients will receive zunsemetinib by mouth (PO) twice per day (BID) at an assigned dose. In general, capecitabine will be taken twice daily at a dose of 1000 mg/m\^2 on Days 1 through 14 of every 21-day cycle. The first 4 patients enrolling to phase II will take capecitabine on a different schedule for PK purposes in Cycles 1 and 2 ONLY. Patients will take capecitabine at a dose of 1000mg/m\^2 on Days 2 through 15 of Cycles 1 and 2, and then on Days 1 through 14 starting with Cycle 3. If only one dose level of zunsemetinib plus capecitabine was found tolerable in phase Ib testing, the phase II trial will proceed with 2:1 two-arm randomization with Arm 2 of capecitabine plus zunsemetinib and Arm 1 of capecitabine plus standard of care anti-resorptive agent.
Polyvalent vaccines against leprosy are prepd. from at least one form of Hansen bacillus, i.e . BAAR (acid-resistant bacilli), cyanophilic forms, form 2, form 3, or mixts. of some or all of these forms, obtd. from cultures in suitable selected media, of leprous inoculums which are leprous serums, leprous bacillary suspensions, filtrates of leprous bacillary suspension not treated with decontaminants, ground leprous tissue, filtrates of BAAR cultures lysed on Lowensteins medium, aged BAAR cultures, these inoculums being used alone or in mixts. then transplanting the leprous strains obtd. into a suitable maintenance medium, and stopping the multiplication of the cultures by any appropriate sterilisation technique. The product is then subdivided into unit doses for the prophylactic treatment of leprosy. The method overcomes the known difficulties of prepg. leprosy vaccine.
An alternative to culling male hatchlings of layers is breeding dual-purpose chickens. One breeding objective is the ability to digest low-quality feed. Certain measurements of the gastrointestinal tract may be useful indicators of this ability. The present study compared the gastrointestinal tract of adult hens of two layer-type breeds (White Rock (WR), New Hampshire (NH)) and the meat-type ÖTZ (Ökologische Tierzucht gGmbH) Bresse Gauloise (BR), used for the production of dual-purpose organic chickens. Flocks had the same housing and feeding conditions. At slaughter at 19 months, the body weight and gastrointestinal organs of 134 hens (51 WR, 55 NH and 28 BR) were measured. The muscle thickness of the proventriculus and ventriculus and the length and width of the duodenum, jejunoileum, caeca and colorectum were measured and variances between the groups were analysed using a one-factor covariance analysis. Significant differences between the breeds were found in total intestine length and the lengths and/or widths of single gastrointestinal segments. For example NH showed the highest mean total intestinal length and BR showed the lowest mean (NH: 186.73 cm, WR 185.86 cm, BR 157.91 cm; p = 0.001). To our knowledge, this is the first study comparing the gastrointestinal tract size of adult female layer- and meat-type chicken breeds kept under the same feeding and housing conditions. Given the possible relationship between intestinal length parameters and chicken performance, measurement of the gastrointestinal tract may be a simple, quick and inexpensive additional method to help select layer-, meat-type and dual-purpose chickens suitable for organic production when a selection process using genetic markers is not possible.
A blood pressure of MAP \> 60 mmHg is used during extracorporeal circulation. The higher MAP is maintained by using continuous intravenous administration of norepinephrine titrated to the appropriate dose for each patient.
Title compsn. with high abrasion props. low water retention, layer structure, low specific surface and low oil absorption are made by (1) acidifying an alkali metal silicate soln. to the onset of ppn., (2) interrupting the addition of acid e.g. for 10 mins.-2 hours and allowing the mixt. to ripen, (3) adding more acid to complete the ppn. and (4) filtering, washing and drying the ppte. In general a Na silicate solution is acidified with aqs. H2SO3, HCl, HNO3, acetic acid or formic acid soln. until just opalescent, the mixt. is then aged for 10-15 mins. and acidification then continued to a pH of 5-7 to complete the pptn. The ppte. filters rapidly and the filter cake has low water retention. Products are useful as molecular sieves, matting agents, carriers, fillers and viscosity control agents, and especially as fillers in toothpastes, e.g. of the clear gel type.
* Neffy is for nasal use only.
  * Each neffy nasal spray is for single use and delivers the entire dose upon activation.
  * Do not prime or attempt to reuse neffy for more than one administration.
  * Use the right hand to administer neffy to the right nostril and use the left hand to administer neffy to the left nostril.



Administer neffy by inserting the nozzle of the nasal spray fully into one nostril until your fingers touch the nose (see Figure 1). Hold the nasal spray straight into the nose - do not angle the nasal spray to the inside septum or outer wall of the nose as some medication may be lost. Press the plunger firmly to activate. Avoid sniffing during and after administration. If a second dose of neffy is needed, administer a new nasal spray into the same nostril starting 5 minutes after the first dose. More than two sequential doses of epinephrine should be administered under direct medical supervision. Refer patients and caregivers to the Instructions for Use for detailed administration instructions.

Figure 1: Administration of Neffy

If neffy is frozen and is needed in an emergency, do not wait to thaw, seek emergency medical care immediately [see How Supplied/Storage and Handling (16)].
Patients receive interleukin-12 IV over 5-15 seconds on day 1 and interferon alfa subcutaneously on days 2-6. Treatment repeats every 2 weeks in the absence of unacceptable toxicity. Patients are reassessed after 6 courses. Patients with a complete response receive 2 additional courses. Patients with a partial response or stable disease continue treatment in the absence of disease progression.